By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Contraceptives > Ethinyl estradiol and segesterone (vaginal ring) > Ethinyl estradiol and segesterone (vaginal ring) Side Effects
Contraceptives

Ethinyl estradiol / segesterone Side Effects

Applies to ethinyl estradiol / segesterone: vaginal insert extended release.

Warning

Vaginal route (Insert, Extended Release)

Warning: Cigarette Smoking and Serious Cardiovascular EventsFemales over 35 years old who smoke should not use segesterone acetate/ethinyl estradiol vaginal system. Cigarette smoking increases the risk of serious cardiovascular events from combination hormonal contraceptive (CHC) use.

Serious side effects

Along with its needed effects, ethinyl estradiol/segesterone may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking ethinyl estradiol / segesterone:

More common

  • Bladder pain
  • bloody or cloudy urine
  • chills
  • difficult, burning, or painful urination
  • fever
  • frequent or painful urination
  • headache, severe and throbbing
  • itching of the vagina or outside the genitals
  • lower back or side pain
  • pain during sexual intercourse
  • stomach pain
  • thick, white curd-like vaginal discharge without odor or with mild odor
  • upper or lower abdominal pain

Less common

  • Anxiety
  • back pain
  • chest pain
  • confusion
  • cough
  • dizziness or lightheadedness
  • expulsion of tissue with clots from your vagina
  • fainting
  • fast heartbeat
  • hives, itching, skin rash
  • hoarseness
  • irritation
  • joint pain, stiffness or swelling
  • mental depression
  • mood or other mental changes
  • numbness of the hands
  • pain, redness, or swelling in the arm or leg
  • redness of the skin
  • severe stomach pain
  • swelling of the eyelids, face, lips, hands, or feet
  • tightness in the chest
  • troubled breathing or swallowing

Other side effects

Some side effects of ethinyl estradiol / segesterone may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Cramps
  • diarrhea
  • heavy bleeding
  • nausea
  • normal menstrual bleeding occurring earlier, possibly lasting longer than expected
  • vomiting

For Healthcare Professionals

Applies to ethinyl estradiol / segesterone: vaginal ring.

General

The more commonly reported adverse reactions have included headache/migraine, nausea/vomiting, vulvovaginal mycotic infection/candidiasis, upper and lower abdominal pain, dysmenorrhea, and vaginal discharge; 25% of women reported at least 1 complete expulsion of vaginal system during use.[Ref]

Cardiovascular

Combination Hormonal Contraceptives (CHC):

Uncommon (0.1% to 1%): Venous thrombotic event (VTE) rate

Frequency not reported: Increased blood pressure

Segesterone and Ethinyl Estradiol Vaginal System:

Frequency not reported: Venous thrombotic events (VTEs)

Serious adverse reactions occurred in 2% or more of subjects in clinical trials and included VTEs (deep vein thrombosis, cerebral vein thrombosis, and pulmonary embolism). At about 50% enrollment, females with BMI greater than 29 kg/m2 were excluded from participation due to the occurrence of 2 VTEs in this subgroup.

The rate of VTE in females using CHC has been estimated at 3 to 12 cases per 10,000 women. The risk of VTE for females who are not pregnant and do not use CHC is estimated to be between 1 and 5 for 10,000 women. For pregnant women, the risk is estimated to be 5 to 20 per 10,000 women and for those through 12 weeks postpartum, 40 to 65 per 10,000 women.

Local

One complete vaginal system expulsion was experienced by 25% of women during clinical trials; 1.4% of patients discontinued use due to vaginal system expulsions.

Very common (10% or more): Vaginal system expulsion

Hypersensitivity

Frequency not reported: Hypersensitivity reactions

Serious adverse reactions occurred in 2% or more of subjects in clinical trials and included drug hypersensitivity. Hypersensitivity reactions included throat constriction, facial edema, urticaria, hives, and wheezing.

Nervous system

Very common (10% or more): Headache, including migraine (38.6%)

Hepatic

An estimate of the attributable risk of hepatic adenomas associated with CHC use is 3.3 cases per 100,000 CHC users.

Combination Hormonal Contraceptives (CHC):

Very rare (less than 0.01%): Hepatic adenomas

Segesterone and Ethinyl Estradiol Vaginal System:

Frequency not reported: Liver enzyme elevations (with concomitant hepatitis C treatment)

Gastrointestinal

Combination Hormonal Contraceptives (CHC)

Frequency not reported: Gallbladder disease (new onset or worsening)

Segesterone and Ethinyl Estradiol Vaginal System:

Very common (10% or more): Nausea/vomiting (25%), Abdominal pain/lower/upper (13.3%)

Common (1% to 10%): Diarrhea

Genitourinary

Very common (10% or more): Vulvovaginal mycotic infection/vaginal candidiasis (14.5%), dysmenorrhea (12.5%), vaginal discharge (11.8%)

Common (1% to 10%): Unscheduled (breakthrough) bleeding, amenorrhea, UTI/cystitis/pyelonephritis/genitourinary tract infection, metorrhagia/menstrual disorder, genital pruritus

Frequency not reported: Metrorrhagia, menorrhagia, abnormal withdrawal bleeding

Endocrine

Common (1% to 10%): Breast pain/discomfort

Frequency not reported: Spontaneous abortions

Serious adverse reactions occurred in 2% or more of subjects in clinical trials and included spontaneous abortions.

Psychiatric

Serious adverse reactions occurred in 2% or more of subjects in clinical trials and included psychiatric events. These events were not further defined.

Frequency not reported: Psychiatric events

Oncologic

Combination Hormonal Contraceptives (CHC)

Very rare (less than 0.01%): Hepatocellular carcinoma

The risk of long-term CHC users developing hepatocellular carcinomas is less than 1 case per million users. Long-term use is greater than 8 years.

Share this Article
Latest News
Medical News

Obesity, unhealthy lifestyles may cause heart to age by 5–45 years

May 08, 2025
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Heart disease: Just 3 minutes of 'incidental activity' may lower...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by